Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
about
Drugging MYCN through an allosteric transition in Aurora kinase AAurora Kinase Inhibitors: Current Status and OutlookCell Proliferation in NeuroblastomaScientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in CancerTranscriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.Potential approaches to the treatment of Ewing's sarcomaExploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationOverview and recent advances in the treatment of neuroblastoma.Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationFOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.Neuroblastoma in Africa: A Survey by the Franco-African Pediatric Oncology Group.Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.Update on aurora kinase inhibitors in gynecologic malignancies.Update on Aurora Kinase Targeted Therapeutics in Oncology.Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.Aurora B kinase is a potent and selective target in MYCN-driven neuroblastomaMolecular profiling of childhood cancer: Biomarkers and novel therapiesAdditive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell linesNeuroblastoma treatment in the post-genomic era.Children's Oncology Group's 2013 blueprint for research: neuroblastoma.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Emerging drugs for neuroblastoma.New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.Molecular biology of pediatric brain tumors and impact on novel therapies.The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosisAssessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology EuroThe Aurora kinase inhibitors in cancer research and therapy.An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation.Advances in emerging drugs for the treatment of neuroblastoma.Genetic susceptibility to neuroblastoma.Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.LIN28B: an orchestrator of oncogenic signaling in neuroblastoma.Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
P2860
Q24303381-7828C856-24A4-403B-9DA8-AA952ECFE54AQ26770583-731D5983-3D44-4125-AB22-EA2B7AC8591EQ26771708-A527B08E-9BE3-462E-BB12-781E2844923CQ26784060-19DB3DE1-64C5-4D72-8387-8B9B8E0AD735Q27853347-EEADDE69-D15D-4D04-A9D1-C42086BADAB0Q28072744-071D0D56-875A-4423-A8C2-17407889495EQ28118450-4C5C11D5-B9FD-4358-B9D3-74CC72C1C1E2Q30238693-8B3A47F8-7E21-432D-8B69-C761399D1560Q33430055-3AE078D9-760B-492D-BC3E-074FEF06B0B6Q33566511-65734F8C-6A85-48BC-82BF-AA8A4B40A2C1Q33835928-9670E44A-7DC8-4650-AD7E-189EEE7ACE67Q33872797-EAD63F77-474A-494C-B32D-6C78E0EF751FQ34264571-313D0A4A-5F0E-4659-A85F-89E3158B79A6Q34281881-25AE5355-B82F-4D23-858B-DA9DF6654BFCQ34576017-8B2603D5-370D-47B1-9380-EC1146EF567AQ34941504-A3164750-DF78-46EB-9733-48E2AB545CC9Q35789013-8C1A9C55-AA7C-4680-BF7D-4CA2D0BE4A60Q35819646-C87E32C5-8833-4CF7-8EA8-6B29C8762DA9Q36250783-876B341D-E1A7-471C-9C0D-1DBECAB36505Q36849233-FDD010A3-37C2-4F26-AF7D-BA5A6EA0CB8CQ37633731-3466B2D7-958B-4670-A18E-C10E2AEC9AB3Q38068818-FA24E0B9-AFDD-4D32-B5E7-AFF5667455D0Q38099046-D606C9E5-D039-45CB-8913-90570FAD5098Q38108399-E9BCA301-7EEF-4C10-94B2-6B2B89FC507EQ38130615-F1020665-0755-4386-98DD-50A8D51B8FD2Q38295876-C7EC3253-B257-4D21-A056-7B12BFD88803Q38359284-5310AFC8-C3A5-4A00-9799-107B0AD35256Q38700629-8A81C5B1-4561-4829-A181-8AE406F967FFQ38705079-E5D994C9-42B2-4387-8598-D46E283D6403Q38730798-757C9493-6AA9-489A-A3F6-F435F2CCE5DBQ38756932-49A5340B-35CF-4610-94BE-F121CAD05BC9Q38783162-DDAD4024-FF39-47BE-9169-924012E7B878Q38961012-9816F06C-EEC8-4265-9C9B-68B48A1F205EQ38973422-5427E58A-F7FF-4BA7-8189-25D9319997C9Q39158415-2AB43273-0DD0-421E-AB0B-6C30DB496488Q39273903-2F44E746-5A5B-48B3-B30A-182368BAA2B2Q40041609-1E2780C0-0013-49B9-B392-E802DA26936AQ40652230-2CD4F43B-6C2A-42B5-A8B8-9AD9F75D5ED9Q47447546-221F9948-4DA4-4628-8A40-DEF3EC0069C0Q47671054-ED4013DD-AA21-4967-BB8B-7EF36F94A06E
P2860
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@ast
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@en
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@nl
type
label
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@ast
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@en
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@nl
prefLabel
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@ast
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@en
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@nl
P2093
P2860
P1476
Pediatric phase I trial and ph ...... roup Phase I Consortium study.
@en
P2093
Brenda Weigel
Charlotte H Ahern
David T Teachey
Elizabeth Fox
Emily Lipsitz
John M Maris
Mark A Ingle
Peter C Adamson
Yael P Mossé
P2860
P304
P356
10.1158/1078-0432.CCR-11-3251
P407
P577
2012-09-17T00:00:00Z